002720 — Kukje Pharma Co Balance Sheet
0.000.00%
- KR₩94bn
- KR₩115bn
- KR₩156bn
Annual balance sheet for Kukje Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 4,273 | 7,903 | 5,559 | 10,632 | 8,755 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 23,937 | 23,486 | 20,359 | 22,141 | 24,656 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 49,940 | 48,197 | 48,535 | 55,119 | 56,974 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 86,986 | 81,981 | 78,380 | 99,124 | 98,185 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 145,626 | 139,783 | 136,593 | 163,259 | 165,548 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 55,358 | 54,517 | 47,855 | 59,687 | 28,547 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 75,143 | 71,215 | 62,519 | 78,315 | 76,006 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 70,482 | 68,568 | 74,074 | 84,944 | 89,542 |
Total Liabilities & Shareholders' Equity | 145,626 | 139,783 | 136,593 | 163,259 | 165,548 |
Total Common Shares Outstanding |